Celularity CELU 深 沪
等待开盘 09-16 09:30:00 美东时间
1.24
-0.160
-11.43%
华盛通- 最 高1.40
- 今 开1.33
- 成交量 14.82万股
- 最 低 1.24
- 昨 收 1.40
- 总市值 3589.30万
- 52周最高 2.55
- 市盈率 静 --
- 换手率 0.51%
- 52周最低 0.5601
- 委 比 44.43%
- 总股本 2894.60万
- 历史最高 134.00
- 量 比 0.86
- 振 幅 11.43%
- 历史最低 0.5601
- 每 手 1
- 风险率 0.47%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Celularity Restores Nasdaq Compliance on Key Listing Standards
Celularity ( ($CELU) ) has provided an update. On September 11, 2026, Celularit...
09-14 21:29
Why Is Celularity Stock Gaining Thursday?
Celularity Inc. (NASDAQ:CELU) stock surged Thursday after the company announced a U.S. manufacturing collaboration with MuseCell Innovations. Under the agreement, Celularity will work to establish U.S. production of Dezawa MuseCells at its facility in Florham Park, New Jersey. Deal Could Expand The ...
08-28 01:42
Celularity shares are trading higher after the company announced an additional U.S.-based manufacturing collaboration under which Celularity will undertake activities to establish U.S. production of Dezawa MuseCells at Celularity’s Florham Park, New Jersey facility.
Celularity shares are trading higher after the company announced an additional U.S.-based manufacturing collaboration under which Celularity will undertake activities to establish U.S. production of Dezawa MuseCells at Celularity’s Florham Park, New Jersey facility.
08-27 22:18
Celularity Provides Update Regarding Nasdaq Listing Compliance
Celularity Inc. received a notice from Nasdaq due to failure to file its Q2 and Q1 2026 10-Q reports, violating Listing Rule 5250(c)(1). The company must submit a compliance plan by September 4, 2026, with a maximum 180-day extension until November 16, 2026. The stock continues to trade on Nasdaq, and the company is working to file both reports as soon as possible.
08-25 23:59
NEXGEL ANNOUNCES LEADERSHIP TRANSITION AND STRATEGIC REVIEW INITIATIVE
NEXGEL, Inc. announced leadership changes and strategic initiatives to enhance operational execution and shareholder value. Brian Kieser was appointed Interim CEO, while Adam Levy stepped down. A Special Committee for Strategic Review and Value Creation was formed to evaluate operations, asset portfolio, and strategic direction. The company aims to improve liquidity, operational efficiency, and focus on high-value growth opportunities, including ...
08-20 20:05
Celularity Receives Nasdaq Noncompliance Notice
- Celularity Inc. (NASDAQ:CELU) (the "Company"), a longevity-focused regenerative and cellular medicine company, today announced that it received a notification letter on May 27, 2026, from the Listing Qualifications
05-30 05:17
Celularity Enters Settlement With Helena Global To Restructure Convertible Note Obligations, Including $500K Upfront And $100K Monthly Payments Plus Note Assignment
Entry into a Material Definitive Agreement. As previously disclosed by Celularity Inc. (the "Company") in its Current Report on Form 8-K filed on April 21, 2026, Helena Global Investment Opportunities 1 Ltd.
05-29 05:24
美股夜盘 | Cabaletta Bio涨17.35%，Freshpet Inc涨16.04%
阿卡迪亚医疗保健涨-14.11%；Akanda Corp涨-10.28%；联掌门户涨-9.43%
05-04 08:05
Celularity Receives Nasdaq Notice Regarding Late Form 10-K Filing
Celularity Inc. (NASDAQ:CELU) (the "Company"), a longevity-focused regenerative and cellular medicine company, today announced that on April 16, 2026, the Company received notification from the Listing Qualifications
04-18 04:38
